3 Results for "

solvent-front

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "solvent-front" in MCE Product Catalog:

Cat. No.: HY-175302
CAS No.: 3044124-79-7
Target:  

Trk Receptor Apoptosis

Research Areas:  

Cancer

TRK-IN-32 is a potent TRK inhibitor. TRK-IN-32 potently inhibits TRK WT, TRK G595R and TRK G667C with IC50 values of 0.08 nM, 2.14 nM and 0.68 nM, respectively. TRK-IN-32 also demonstrates antiproliferative activity against a panel of Ba/F3 cell lines transformed with wild type, xDFG, solvent-front as well as gatekeeper mutant TRK fusion proteins. TRK-IN-32 induces apoptosis of Ba/F3-TRKA WT and Ba/F3-TRKA G667C cells.TRK-IN-32 can be used for the study of various cancers (such as thyroid cancer, secretory breast carcinoma) .
loading...
    loading...
Cat. No.: HY-170926
Target:  

RET Apoptosis

Research Areas:  

Cancer

CQ1373 is a potent RET inhibitor, demonstrating cellular potency with IC50 values of 13.0, 25.7 and 28.4 nM against BaF3 cells expressing CCDC6-RET, CCDC6-RET-G810C and CCDC6-RET-G810R, respectively. CQ1373 exhibits good selectivity toward wild-type RET and solvent front mutants G810C/R with IC50 values of 4.2, 7.1 and 32.4 nM, respectively. CQ1373 inhibits RET phosphorylation and downstream signaling through SHC. CQ1373 induces Apoptosis and cell cycle arrest in BaF3 cells. CQ1373 exhibits anti-tumor efficacy and can be used for cancer research .
loading...
    loading...
Cat. No.: HY-189268
Target:  

RET

Research Areas:  

Endocrinology Cancer

RET-IN-36 is an orally active RET kinase inhibitor. RET-IN-36 overcomes gatekeeper and solvent front resistance mutations and inhibits the proliferation of cells expressing RET G810C and RET V804M mutants by suppressing RET phosphorylation and SHC downstream signaling. RET-IN-36 can be used for research on RET-mutant cancers, medullary thyroid cancer, papillary thyroid cancer, and non-small cell lung cancer .
loading...
    loading...